[PDF] MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody,

mbs303MBS-303: a CD20 inhibitors, CD3 stimulants Drug, Initially developed by Beijing Mabworks Biotech Co., Ltd.,MBS303MSC303 (MBS303 as the intravenous formulation, MSC303 as the subcutaneous formulation) is an innovative CD20CD3 T-cell engager. MBS303 has initiated clinical trials